While initially described as a HER2 inhibitor, mubritinib has recently been identified as a direct, ubiquinone-dependent ETC complex I inhibitor and has been exploited to target oxidative phosphorylation (OXPHOS)-dependent leukemia cells29. This evidence concerns the gene ERBB2 and leukemia.